{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:11:41Z","timestamp":1793293901763,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.xkme.2025.101001","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T03:28:18Z","timestamp":1743910098000},"page":"101001","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Hemoadsorption as a Supportive Strategy for Severe Toxicity Associated With Chimeric Antigen Receptor T-Cell Therapy: A Case Series"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0834-5586","authenticated-orcid":false,"given":"Pasquale","family":"Esposito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Gambella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Raiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Beltrametti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Novella","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Porcile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bianzina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Centanaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Viazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Angelucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.xkme.2025.101001_bib1","doi-asserted-by":"crossref","first-page":"7844","DOI":"10.1002\/cam4.5551","article-title":"Chimeric antigen receptor T (CAR-T) cells: novel cell therapy for hematological malignancies","volume":"12","author":"Abbasi","year":"2023","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.xkme.2025.101001_bib2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/BS9.0000000000000173","article-title":"CAR-T cell therapy: where are we now, and where are we heading?","volume":"5","author":"Wang","year":"2023","journal-title":"Blood Sci"},{"key":"10.1016\/j.xkme.2025.101001_bib3","article-title":"CAR-T cell therapy in hematological malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.xkme.2025.101001_bib4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12929-023-00982-8","article-title":"Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies","volume":"30","author":"Yang","year":"2023","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.xkme.2025.101001_bib5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/ITT.S202015","article-title":"Cytokine release syndrome: current perspectives","volume":"8","author":"Murthy","year":"2019","journal-title":"Immunotargets Ther"},{"issue":"8","key":"10.1016\/j.xkme.2025.101001_bib6","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00277-018-3368-8","article-title":"The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review","volume":"97","author":"Jin","year":"2018","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.xkme.2025.101001_bib7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy \u2013 assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.xkme.2025.101001_bib8","article-title":"The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions","volume":"13","author":"Li","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.xkme.2025.101001_bib9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/cc9411","article-title":"Clinical review: Blood purification for sepsis","volume":"15","author":"Rimmel\u00e9","year":"2011","journal-title":"Crit Care"},{"key":"10.1016\/j.xkme.2025.101001_bib10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jcrc.2020.02.010","article-title":"Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome","volume":"57","author":"Stahl","year":"2020","journal-title":"J Crit Care"},{"issue":"11","key":"10.1016\/j.xkme.2025.101001_bib11","first-page":"1860","article-title":"Report of the Committee on Hodgkin\u2019s Disease Staging Classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.xkme.2025.101001_bib12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.xkme.2025.101001_bib13","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/cc11454","article-title":"Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)","volume":"17","author":"Kellum","year":"2013","journal-title":"Crit Care"},{"issue":"6","key":"10.1016\/j.xkme.2025.101001_bib14","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"14","key":"10.1016\/j.xkme.2025.101001_bib15","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.xkme.2025.101001_bib16","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.xkme.2025.101001_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-77720-z","article-title":"Acute kidney injury in hematological patients treated with CAR-T cells: risk factors, clinical presentation and impact on outcomes","volume":"14","author":"Russo","year":"2024","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.xkme.2025.101001_bib18","article-title":"CAR-T cell therapy for hematological malignancies: History, status and promise","volume":"9","author":"Wang","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.xkme.2025.101001_bib19","first-page":"705","article-title":"Spotlight on tocilizumab in the treatment of CAR-T-cell-induced cytokine release syndrome: clinical evidence to date","volume":"16","author":"Si","year":"2020","journal-title":"Ther Clin Risk Manag"},{"issue":"7","key":"10.1016\/j.xkme.2025.101001_bib20","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","article-title":"Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy","volume":"29","author":"Gazeau","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.xkme.2025.101001_bib21","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1093\/ndt\/gfae089","article-title":"Hemoadsorption: consensus report of the 30th Acute Disease Quality Initiative workgroup","volume":"39","author":"Bellomo","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1016\/j.xkme.2025.101001_bib22","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/s41409-020-0896-3","article-title":"Extracorporeal cytokine adsorption for treating severe refractory cytokine release syndrome (CRS)","volume":"55","author":"Wallet","year":"2020","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"10.1016\/j.xkme.2025.101001_bib23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1159\/000492379","article-title":"Clinical utility of extracorporeal cytokine hemoadsorption therapy: a literature review","volume":"46","author":"Bonavia","year":"2018","journal-title":"Blood Purif"},{"issue":"5","key":"10.1016\/j.xkme.2025.101001_bib24","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1159\/000080235","article-title":"Cytokine removal with a novel adsorbent polymer","volume":"22","author":"Song","year":"2004","journal-title":"Blood Purif"},{"issue":"1","key":"10.1016\/j.xkme.2025.101001_bib25","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13054-017-1662-9","article-title":"Hemoadsorption by CytoSorb in septic patients: a case series","volume":"21","author":"Kogelmann","year":"2017","journal-title":"Crit Care"},{"issue":"4-5","key":"10.1016\/j.xkme.2025.101001_bib26","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1159\/000511725","article-title":"Hemoperfusion with CytoSorb as adjuvant therapy in critically ill patients with SARS-CoV2 pneumonia","volume":"50","author":"Rampino","year":"2021","journal-title":"Blood Purif"},{"issue":"10","key":"10.1016\/j.xkme.2025.101001_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187015","article-title":"The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: a randomized controlled trial","volume":"12","author":"Sch\u00e4dler","year":"2017","journal-title":"PLOS One"},{"key":"10.1016\/j.xkme.2025.101001_bib29","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jcrc.2021.04.011","article-title":"High-dose CytoSorb hemoadsorption is associated with improved survival in patients with septic shock: a retrospective cohort study","volume":"64","author":"Schultz","year":"2021","journal-title":"J Crit Care"},{"issue":"4","key":"10.1016\/j.xkme.2025.101001_bib30","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2478\/jccm-2022-0028","article-title":"Successful extracorporeal blood purification therapy using double haemoadsorption device in severe endotoxin septic shock: a case report","volume":"8","author":"Ferraro","year":"2022","journal-title":"J Crit Care Med (Targu Mures)"},{"issue":"1","key":"10.1016\/j.xkme.2025.101001_bib31","article-title":"Multimodal therapeutic approach of cytokine release syndrome developing in a child given chimeric antigen receptor-modified T cell infusion","volume":"2","author":"Bottari","year":"2020","journal-title":"Crit Care Explor"},{"issue":"7","key":"10.1016\/j.xkme.2025.101001_bib32","article-title":"Novel use of extracorporeal blood purification for treatment of severe, refractory neurotoxicity after chimeric antigen receptor T-cell therapy-a case report","volume":"3","author":"Singbartl","year":"2021","journal-title":"Crit Care Explor"},{"issue":"10416","key":"10.1016\/j.xkme.2025.101001_bib33","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059525000378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059525000378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T20:29:54Z","timestamp":1762633794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059525000378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2590059525000378"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2025.101001","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemoadsorption as a Supportive Strategy for Severe Toxicity Associated With Chimeric Antigen Receptor T-Cell Therapy: A Case Series","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2025.101001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101001"}}